Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
New York Med Coll
Valhalla, NY 10595
Education & Training
New York Medical CollegeClass of 2015
Certifications & Licensure
IL State Medical License 2021 - 2026
IN State Medical License 2023 - 2025
TX State Medical License 2018 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer Start of enrollment: 2021 Jun 01
Roles: Contact
- CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer Start of enrollment: 2022 Apr 20
Roles: Contact
Publications & Presentations
PubMed
- A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.Nan Chen, Margarite Matossian, Poornima Saha, Murtuza Rampurwala, Salaija Kamaraju
Breast Cancer Research and Treatment. 2025-02-10 - Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US.Jincong Q Freeman, Dezheng Huo, Sarah P Shubeck, Nan Chen, Sudha R Yarlagadda
JAMA Network Open. 2025-02-03 - High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.Margarite D Matossian, Christine Shiang, Deniz Nesli Dolcen, Marie Dreyer, Ken Hatogai
Breast Cancer Research and Treatment. 2025-02-01
Press Mentions
Recurrence Scores from 21-Gene Assay Help Inform Benefits of Adjuvant Anthracyclines in EBCJanuary 25th, 2025- Predicting Treatment Response in Patients with HR-Positive, HER2-Negative Breast CancerDecember 16th, 2024
- Homing in on Anthracyclines' High-Risk Niche in Early Breast CancerDecember 14th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
